drugset / Trial / NCT04305678

Mepolizumab for Eosinophilic Fasciitis

NCT04305678

NaSingle-groupOpen-labelTreatment

Summary

This is a proof of concept pilot study to investigate the efficacy of mepolizumab in the treatment of eosinophilic fasciitis.

Timeline

Start
2023-02
Primary completion
2023-02-15
Completion
2023-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepolizumab Monoclonal antibody 400 mg Other